Home / Executive Moves / Carol Goode, Yvette Kanouff Named to SAIC Board; Donna Morea Quoted

Carol Goode, Yvette Kanouff Named to SAIC Board; Donna Morea Quoted

Science Applications International Corp. (NYSE: SAIC) has named human resources executive Carol Goode and Yvette Kanouff, a partner and chief technology officer at Silicon Valley-based private equity firm JC2 Ventures, to SAIC’s board of directors.

Goode will serve on SAIC’s HR and compensation committee and nominating and corporate governance panel, while Kanouff join the firm’s audit and risk oversight committees, SAIC said Thursday.

Donna Morea, board chair at SAIC, said Goode and Kanouff bring to the board decades of leadership experience in talent acquisition, technology development and strategy implementation areas.

“Carol and Yvette’s counsel and expertise will bring energy to our board and strengthen SAIC’s commitment to talent development and enhancing mission-critical solutions to better serve our employees, customers, and shareholders,” Morea added.

Goode is a board member at WageWorks (NYSE: WAGE) and an HR adviser to several clients in the San Francisco Bay Area. She previously served as chief HR officer at Brocade Communications and held HR leadership roles at Seagate and Nortel Networks.

Kanouff serves as a board member at management software firm Sprinklr. She held leadership roles at several companies including Cisco Systems’ (Nasdaq: CSCO) service provider business, Time Warner, Cablevision and SeaChange International.

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.